1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gubra A/S

Gubra A/S

GUBRA.CO
Gubra A/SDK flagNASDAQ Copenhagen
363.80
DKK
+3.40
- -
5.97BMarket Cap
Gubra A/S
GUBRA.CO
(NASDAQ Copenhagen)

Recent

price

363.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
- -
10.54
15.62
12.19
13.51
16.3
- -
Revenue per Share
- -
0.78
4.16
0.26
-2.93
-2.24
- -
Basic EPS, GAAP
- -
1.58
3.75
0.62
-4
-1.66
- -
Free Cash Flow per Basic Share
- -
- -
0.41
4.04
4.5
- -
- -
Dividend per Share
- -
4.89
9.26
6.62
31.62
27.64
- -
Book Value per Share
- -
4.82
9.04
6.17
30.85
26.7
- -
Tangible Book Value per Share
- -
16
16
16
15
16
- -
Basic Weighted Avg Shares
- -
172
255
199
205
266
2,637
Sales/Revenue/Turnover
- -
9.21
34.73
-0.65
-23.25
-18.82
81.54
Operating Margin (%)
- -
9
10
7
10
16
17
Depreciation Expense
- -
13
68
4
-45
-36
1,691
Net Income, GAAP
- -
7.23
22
31.14
- -
- -
21.54
Effective Tax Rate (%)
- -
7.37
26.61
2.16
-21.72
-13.73
64.11
Profit Margin (%)
37
54
103
98
458
402
1,075
Working Capital
50
52
46
61
61
82
89
LT Debt
64
80
151
108
480
451
1,146
Total Equity
- -
11.32
40.39
-0.46
- -
- -
187.37
Return on Invested Capital (%)
- -
10.74
40.44
2.81
- -
- -
188.39
Return on Capital (%)
- -
17.66
58.7
3.32
-15.15
-7.85
211.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
110.46%
154.33%
Free Cash Flow
- -
-1,408.84%
-6,348.21%
Net Income, GAAP
- -
-1,108.28%
-4,731.94%
Sales/Revenue/Turnover
- -
190.2%
892.25%
Total Cash Common Dividend
- -
- -
1,364%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
205
2024
- -
- -
- -
- -
266
2025
- -
- -
- -
- -
2,637

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.93
2024
- -
- -
- -
- -
-2.24
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.5
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Peptron, Inc. (087010.KQ)
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Moolec Science S.A. (MLEC)
Organovo Holdings, Inc. (ONVO)
Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
Kexing Biopharm Co., Ltd. (688136.SS)
Business
Gubra A/S (GUBRA.CO) is a Denmark-based biotechnology company that specializes in high-end preclinical contract research organization (CRO) services and peptide-based drug discovery focused on metabolic and fibrotic diseases; its operations span Europe, North America and other international markets from headquarters in Hørsholm, Denmark, where it was founded in 2008. The company delivers comprehensive preclinical research solutions including in vivo pharmacology, ex vivo assays, drug profiling, pharmacokinetics, biomarker assays, bioinformatics, next-generation sequencing (NGS), 2D and 3D histology with artificial intelligence pathology, stereology, and whole brain and organ imaging; these services target disease areas such as liver (MASH), obesity, kidney (DKD/CKD/PKD/AKI), diabetes, central nervous system (CNS), lung (IPF), and non-rodent studies in miniature pigs, serving pharmaceutical and biotechnology clients including 16 of the top 20 global pharmaceutical companies. Gubra organizes activities into two synergistic segments: CRO Services, which generates steady cash flow through specialized preclinical studies in translatable rodent and non-rodent models, and Discovery & Partnerships (D&P), which identifies and develops peptide-based drug candidates like amylin analogs and urocortin-2 (UCN2) programs for obesity for potential partnering with development milestone payments and royalties. Recent developments include a March 2025 license agreement with AbbVie granting global rights to develop GUB014295, a long-acting amylin analog for obesity treatment, providing a $350 million upfront payment and up to $1.875 billion in milestones; ongoing partnerships with Boehringer Ingelheim for obesity, Hemab ApS for bleeding disorders, and seven active collaborations overall; preparation for a first-in-human study of its UCN2 obesity program in early 2026; maintenance of full-year 2025 CRO growth guidance at 20% amid solid European demand; and evaluation of merger, acquisition, and pipeline expansion opportunities using AbbVie proceeds.